Genmab A/S announced today, October 21, 2025, that it is commencing a cash tender offer through its wholly‑owned subsidiary Genmab Holding II B.V. to purchase all issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) at a price of $97.00 per share, less applicable withholding taxes and without interest.
The tender offer is being made pursuant to the transaction agreement dated September 29, 2025, and is subject to the conditions set forth in the tender offer statement filed with the U.S. Securities and Exchange Commission. Merus shareholders are advised to review the offer documents, including the SEC Schedule TO and the Board‑recommended acceptance letter, before deciding to tender their shares.
The offer will expire at 5:00 p.m. New York City time on December 11, 2025, unless extended under the terms of the transaction agreement. If the conditions for consummation are satisfied, a subsequent offering period will begin on the first business day after expiration, allowing additional shares to be tendered at the same consideration. This tender offer marks a key step in Genmab’s strategy to acquire Merus and expand its oncology pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.